Iclusig and Nosebleed - a phase IV clinical study of FDA data

Summary:

Nosebleed is reported as a side effect among people who take Iclusig (ponatinib hydrochloride), especially for people who are male, 30-39 old, have been taking the drug for 1 - 6 months also take Valtrex, and have Chronic myeloid leukaemia.

The phase IV clinical study analyzes which people have Nosebleed when taking Iclusig. It is created by eHealthMe based on reports of 6,108 people who have side effects when taking Iclusig from the FDA, and is updated regularly.

What is Iclusig?

Iclusig has active ingredients of ponatinib hydrochloride. eHealthMe is studying from 6,109 Iclusig users. Check the latest studies of Iclusig.

What is Nosebleed?

Nosebleed (bleeding from nose) is found to be associated with 2,076 drugs and 3,093 conditions by eHealthMe. Check the latest studies of Nosebleed.

On Jul, 12, 2026

6,108 people reported to have side effects when taking Iclusig.
Among them, 29 people (0.47%) have Nosebleed.

Among these 29 people:

How long have people been on Iclusig when they have Nosebleed? *

What is the gender of people who have Nosebleed when taking Iclusig? *

female: 34.78 %
male: 65.22 %

What is the age of people who have Nosebleed when taking Iclusig? *

What are other drugs people take besides Iclusig? *

What are other side effects people have besides Nosebleed? *

Headache (pain in head): 12 people, 41.38%
Fatigue (feeling of tiredness): 9 people, 31.03%
Diarrhea: 7 people, 24.14%
Vision Blurred: 7 people, 24.14%
Abdominal Pain Upper: 7 people, 24.14%
Thrombocytopenia (decrease of platelets in blood): 6 people, 20.69%
Paleness (unusual lightness of skin colour): 6 people, 20.69%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 6 people, 20.69%
Weight Decreased: 6 people, 20.69%
Depression: 5 people, 17.24%

What are the existing conditions these people have? *

Chronic Myeloid Leukaemia (long lasting type of cancer that starts in the blood-forming cells of the bone marrow and invades the blood): 24 people, 82.76%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 3 people, 10.34%
Gout (uric acid crystals building up in the body): 2 people, 6.90%
Blast Crisis In Myelogenous Leukaemia: 2 people, 6.90%
Acute Myeloid Leukaemia Recurrent (acute cancer in which the bone marrow makes abnormal myeloblast- recurrent): 2 people, 6.90%
Pain: 1 person, 3.45%
Nausea And Vomiting: 1 person, 3.45%
Nausea (feeling of having an urge to vomit): 1 person, 3.45%
Itching: 1 person, 3.45%
Diarrhea: 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Iclusig and have Nosebleed?

- Check whether Nosebleed is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Iclusig:

Iclusig (6,109 reports)

Nosebleed treatments and more:

Nosebleed (92,075 reports)

Browse all side effects of Iclusig:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Nosebleed:

Nosebleed (2,076 drugs)

Browse all the conditions that are associated with Nosebleed:

Nosebleed (3,093 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ponatinib hydrochloride (the active ingredients of Iclusig) and Iclusig (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.